BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701Ā for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on...